JohnPullmanMD

Internal Medicine • Butte, MT

Critical Care Medicine, Hospital Medicine/Hospitalist, Infectious Disease

Infectious Disease Consultant

Join to view full profile

Dr. Pullman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pullman's full profile

Already have an account?

Office
300 W Mercury St
Butte, MT 59701
Phone+1 406-723-1300

Fax+1 406-723-1360

Education & Training

University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1977 - 1980
University of Rochester School of Medicine and DentistryClass of 1977

Certifications & Licensure

MT State Medical License 1982 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2013

Clinical Trials

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
Study of Debio 1450 for Bacterial Skin Infections Start of enrollment: 2015 May 01
Completed
Phase 2
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Completed
Phase 2
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
Completed
Phase 2
Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL Start of enrollment: 2017 Apr 06
Suspended
Phase 2
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. Start of enrollment: 2020 Apr 30
Completed
Phase 2
An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection Start of enrollment: 2019 Aug 02
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

58 citations
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
George R Thompson 3rd, Alex Soriano, Oliver A Cornely, Bart Jan Kullberg, Marin Kollef
Lancet. 2023-01-07
432 citations
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
Ann R. Falsey, Magdalena E. Sobieszczyk, Ian Hirsch, Stephanie Sproule, Merlin L. Robb
The New England Journal of Medicine. 2021-09-29
7 citations
Selective Brain Hypothermia in Acute Ischemic Stroke: Reperfusion Without Reperfusion Injury.
Jae H. Choi, Sven Poli, Michael Chen, Thanh N. Nguyen, Jeffrey L. Saver
Frontiers in Neurology. 2020-11-13